CellType GTM brain

category

market profile

• text: Drug developers seek computational ways to prioritize experiments and bridge gaps between preclinical systems and human biology.
• text: CellType describes an agentic discovery ambition alongside current models for compound response, toxicity translation and patient outcomes.
• text: Biological simulation is a competitive field that includes drug design engines and virtual cell approaches with different commercial models.

personas

• title: VP of discovery biology
  pains:

  • Too many compounds compete for limited experimental screening capacity
  • Computational rankings need credible biological validation before teams act
• title: Head of translational medicine
  pains:

  • Animal and in-vitro findings do not reliably resolve human safety questions
  • Patient selection and biomarker decisions require evidence tied to human biology
• title: Pharma computational biology or data science leader
  pains:

  • Sensitive assay data must remain under the company's control
  • Must demonstrate predictive value on proprietary data and established assay baselines

icp

• text: Pharmaceutical or biotechnology R&D organizations with active compound screening and preclinical development programs.
• text: Pharma teams holding proprietary assays or outcome data and able to evaluate a private deployment, including larger drug developers.

message pillars

• text: Screen unseen compounds computationally before committing experiments.
• text: Translate signals across species to support human safety decisions.
• text: Adapt models using proprietary data in the customer's environment.
• text: Connect preclinical interventions to patient evidence.

objections

• objection: Will simulated predictions hold up in real biological assays?
  response: Review the company's reported oncology validation and agree a prospective benchmark against the buyer's own experimental baseline.
• objection: Will sensitive drug and patient data leave our infrastructure?
  response: The company describes on-premises and VPC deployment; verify security, model access and contractual data handling.
• objection: How does this improve a specific R&D decision?
  response: Select a screening, toxicity or patient-stratification problem and compare predictions with existing decision and assay workflows.

competitors

• name: Recursion
  why: AI-enabled drug discovery company competing for pharma discovery partnerships.
• name: Isomorphic Labs
  why: Develops AI drug design technology for pharmaceutical research.
• name: Aitia
  why: Builds simulation-based biological models for drug discovery using human patient data.

influencers

• name: David van Dijk
  url: https://www.celltype.com/
  why: Co-founder, CEO and Yale professor associated with Cell2Sentence biological foundation model research.

keywords

• AI drug discovery platform
• single cell foundation model
• virtual compound screening
• human toxicity prediction
• preclinical clinical translation
• biological simulation
• pharma AI private deployment

voice

• scientific
• technically specific
• confident and outcome focused

signals

• text: An oncology team has candidate compounds and assays suitable for a prospective screening pilot.
• text: A pharma R&D group is investing in single-cell data, translational modeling or secure AI on proprietary assays.

stack

• VPC
• on-premises deployment
• single-cell RNA data

hiring

• Founding Research Scientist, Biological Foundation Models

pricing

motion

channels

• scientific publications
• LinkedIn
• pharma partnerships
• website

confidence

Founders

• name: David van Dijk
  title: Founder/CEO
  role: CEO
  bio: Co-Founder & CEO of CellType (W26). Yale Professor, 11,000+ citations. Built biological foundation models with Google. Building the agentic drug company.